Connect with us

Cannabis News

Denver-Based OTC Exchange PanXchange Launches Industrial Hemp Pricing As An Industry First Platform



Denver-Based OTC Exchange PanXchange Launches Industrial Hemp Pricing As An Industry First Platform
- Ad -

PanXchange is a Denver-based exchange that deals with OTC physical commodity trading, while also acting as a price reporting provider. In a new development, they have become the first company to offer industrial hemp pricing data to the entire market. The new pricing publication is issued each month, though the trading is not planned for launch until the third quarter of 2019.

Members on PanXchange will be privy to pricing for the following products:

  • FOB Portland, Oregon Hemp Biomass
  • FOB Portland, Oregon Crude Oil
  • FOB Denver, Colorado Hemp Biomass
  • FOB Denver, Colorado Crude Oil
  • FOB Lexington, Kentucky Hemp Biomass
  • FOB Lexington, Kentucky Crude Oil

The lack of good timing has largely been the reason that hemp trading has be available in the past. However, with the recent signing of the Farm Bill of 2018 on December 20th, this industry is prepared for fast and healthy growth. Since the 1970s, the multiple use cases for hemp have not been enough for it to be legalized, but the distinction between hemp and marijuana has made a significant difference, making hemp considered a “commercial commodity, as BusinessWire says.

The industrial hemp production in the United States has been growing. While there were only 9,770 acres planted by 2016, the following year brought in 25,000 acres planted. So far, there are not numbers available for 2018, but early estimates indicate that there is likely to be the equivalent amount of growth.

Julie Lerner, the CEO for PanXchange, said,

“We’re excited to bring transparent pricing and instant market access to another new commodity, particularly a budding commodity like hemp that is just now establishing a legitimate market. The industrial hemp market is brimming with potential and given our deep commodity experience and track record in nascent markets like frac sand, PanXchange is the perfect company to provide this market structure solution that commercial producers have been looking for.”

Despite the influx of interest, hemp is only the second US-focused commodities market that PanXchange supports. Their first is the launch of frac sand, which happened in 2017 when they became the first company to make this product into a market. Last year was good to the industry, as the PanXchange client base presently accounts for almost half of the frac sand that is traded, both online and off. Considering the success in this industry thus far, the PanXchange platform plans to follow the same work that the company did with frac sand in their marketing and management.

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.